福元医药: 北京福元医药股份有限公司关于左甲状腺素钠片获得药品注册证书的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Levothyroxine Sodium Tablets, which will enhance the company's product line and market competitiveness [1][3]. Group 1: Drug Registration Details - The drug is named Levothyroxine Sodium Tablets, with a specification of 100μg [1]. - The drug is classified as a prescription drug and falls under the category of chemical drugs [1]. - The registration certificate was issued by the National Medical Products Administration, confirming that the drug meets the necessary registration requirements [1]. Group 2: Drug Development and Market Information - Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [2]. - The drug was approved for sale in China in July 1997 for various therapeutic uses, including treatment of non-toxic goiter and hypothyroidism [2]. - As of the announcement date, the company has invested a total of RMB 7.57 million in the research and development of this drug [2]. Group 3: Market Status of Similar Drugs - According to data from Minet, the sales revenue of Levothyroxine Sodium Tablets in China for 2024 is approximately RMB 1.14631 billion [2]. - The sales distribution includes RMB 758.17 million from urban public hospitals and county-level public hospitals, RMB 109.20 million from urban community centers and township health centers, and RMB 279.94 million from urban pharmacies and online pharmacies [2].